. Author manuscript; available in PMC: 2018 Feb 9.

Published in final edited form as: Clin Gastroenterol Hepatol. 2008 Dec 27;7(4):487–493. doi: 10.1016/j.cgh.2008.12.018

Table 2.

Biochemical characteristics of patients in clinical trials assessing the efficacy of primary antibiotic prophylaxis in patients with low total protein ascitic fluid.

Author	Total Bilirubin (mg/dL) Rx Group	Total Bilirubin (mg/dL) Placebo Group	Prothrombin time (%)Rx Group	Prothrombin time (%) Placebo Group	Albumin (g/dL) Rx Group	Albumin (g/dL) Placebo Group	Platelet Count (per mm^3) Rx Group	Platelet Count (per mm^3) Placebo Group	Creatinine (mg/dL) Rx Group	Creatinine (mg/dL) Placebo Group	Total Protein, Ascites (g/dL) Rx Group	Total Protein, Ascites (g/dL) Placebo Group
Terg²³	2.9±4.6	2.7±3.2	58±19	57±14	2.7±0.5	2.9±0.6	117,809±72,001	135,655±70,618	0.9±0.3	0.9±0.2	0.84±0.01	0.85±0.36
Novella²²	3.8±0.3	4.1±0.3	60±2	55±3	2.7±0.1	2.7±0.1	N/A	N/A	1.1±0.08	0.9±0.06	1±0.2	0.9±0.1
Grange²¹	5.1±0.8	3.8±0.6	53.1±16.5	55.±14.6	3.29±3.37	2.95±0.55	N/A	N/A	0.8±0.2	0.8±0.1	0.93±0.29	1.04±0.28
Fernandez²⁰	3.5±2.3	4.4±4.6	N/A (INR: 1.49±0.30)	N/A (INR: 1.56±0.36)	2.8±0.6	2.6±0.5	120,314±74,952	94,061±53,571	1.2±0.4	1.2±0.4	0.9±0.4	0.9±0.3